Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (22)

« Back to Publications

Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.

Paganotti Vicentine M. et al, (2026), BMJ Open, 16

Pneumococcal Carriage and Disease in Adults in England, 2011-2019: The Importance of Adults as a Reservoir for Pneumococcus in Communities.

El Safadi D. et al, (2025), J Infect Dis, 231, e17 - e27

Single-cell immune profiling reveals markers of emergency myelopoiesis that distinguish severe from mild respiratory syncytial virus disease in infants.

Zivanovic N. et al, (2023), Clin Transl Med, 13

Salmonella Vaccine Study in Oxford (SALVO) trial: protocol for an observer-participant blind randomised placebo-controlled trial of the iNTS-GMMA vaccine within a European cohort.

Hanumunthadu B. et al, (2023), BMJ Open, 13

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)

EWER K. et al, (2021), The Lancet

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm sub-study of a phase 2/3 clinical trial

EWER K. et al, (2021), Lancet HIV

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Ramasamy MN. et al, (2021), Lancet, 396, 1979 - 1993

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (vol 396, pg 467, 2020)

Folegatti P. et al, (2020), LANCET, 396, 466 - 466

Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU).

Jefferies K. et al, (2020), The Journal of infectious diseases

Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.

Wildenbeest JG. et al, (2020), The Journal of infectious diseases

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

HODGSON S., (2020), The Lancet

Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants

Valente Pinto M. et al, (2020)

Low Sensitivity of BinaxNOW RSV in Infants.

Zuurbier RP. et al, (2020), The Journal of infectious diseases

Persistent circulation of vaccine serotypes and serotype replacement after five years of UK infant immunisation with PCV13

Kandasamy R. et al, (2019), Journal of Infectious Diseases

Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy.

Jeppesen CA. et al, (2015), J Infect, 71, 43 - 52

Load More